Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLife SolutionsBLFS -3.83%71 EV-to-OCF is 75.77 as of Jul. 17, 2026, which is 32% above its 10-year median of 57.42. GuruFocus rates BLFS with a GF Score™ of 71/100 and a GF Value™ of $28.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 93.79% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioLife Solutions's Enterprise Value is $1,356.11 Mil.
BioLife Solutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $17.90 Mil. Therefore, BioLife Solutions's EV-to-OCF for today is 75.77.
The historical rank and industry rank for BioLife Solutions's EV-to-OCF or its related term are showing as below:
BLFS'
s EV-to-OCF Range Over the Past 10 Years
Min: -14195.32 Med: 57.42 Max: 452.84
Current: 75.77
During the past 13 years, the highest EV-to-OCF of BioLife Solutions was 452.84. The lowest was -14195.32. And the median was 57.42.
BLFS's EV-to-OCF is ranked worse than 93.79% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 7.7
vs BLFS: 75.77
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioLife Solutions's PE Ratio (TTM) for today is calculated as:
BioLife Solutions's share price for today is $29.11.
BioLife Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioLife Solutions EV-to-OCF Related Terms
BioLife Solutions EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BioLife Solutions's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's EV-to-OCF falls into.
BioLife Solutions's current Enterprise Value is $1,356.11 Mil.
BioLife Solutions's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a EV-to-OCF of 75.77 as of Jul. 17, 2026. This is 32% above median its historical median of 57.42. According to the industry distribution chart, BioLife Solutions ranks #801 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 93.8%.
Is BioLife Solutions' EV-to-OCF too high?
BioLife Solutions' current EV-to-OCF of 75.77 is 32% above median its 10-year median of 57.42. The Medical Devices & Instruments industry median EV-to-OCF is 7.70. BioLife Solutions' value of 75.77 is 884% above this industry median. Based on the distribution chart, BioLife Solutions ranks #801 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' EV-to-OCF compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #801 out of 854 companies for EV-to-OCF. This places BioLife Solutions in the lower half of its industry. The industry median EV-to-OCF is 7.70. BioLife Solutions' value of 75.77 is 884% above this benchmark. While the company's 10-year median is 57.42 vs. the industry median of 7.70, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.70, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current EV-to-OCF of 75.77 is 884% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current EV-to-OCF is 75.77, which is 32% above median its own 10-year median of 57.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.86, compared to a current price of $29.11 — trading 0.9% above its estimated fair value. The current EV-to-OCF is 75.77, which is 32% above median its 10-year median of 57.42 and 884% above the Medical Devices & Instruments industry median of 7.70. BioLife Solutions' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current EV-to-OCF is 75.77 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $29.11 is trading 0.9% above its estimated GF Value™ of $28.86.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
EV-to-OCF: 75.77 (32% above median its 10-year median of 57.42)
GF Value™: $28.86 vs. price of $29.11 (0.9% above fair value)
Industry Position: 884% above the Medical Devices & Instruments median (#801 of 854)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
71GF Score
Get the complete analysis for BLFS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
